Skip to main content
padlock icon - secure page this page is secure

SEQUENTIAL ADDITION OF DEFEROXAMINE AND HEMIN INHIBITS GLIOMA TUMOR-CELL GROWTH

Buy Article:

$42.00 + tax (Refund Policy)

The toxicity of deferoxamine, a potent iron chelator may be antagonized by hemin a potential iron source. Using the MTT assay we explored the effects of different concentrations and schedules of deferoxamine and hemin or deferoxamine and iron free tin protoporphyrin (SnPP) in two neuroblastoma (VA-N-BR, SK-N-AS), and two glioblastoma multiforme (VA-MG-SL, and U-373 MG) cell lines. In these cell lines, survival after exposure to 10 mug/ml deferoxamine for three days ranged from 28% to 59%. Incubation with hemin alone, had variable effects on growth depending on the cell line. Concomitant exposure to equimolar concentrations of deferoxamine and hemin resulted in the reversal of deferoxamine induced toxicity. Surprisingly, in the glioblastoma multiforme cell lines sequential exposure to deferoxamine and then hemin resulted in additional toxic effects rather than abrogation of deferoxamine toxicity. Sequential exposure of all cell lines to deferoxamine, hemin, and the chemotherapeutic agent thiotepa resulted in enhanced toxicity over any drug used alone. Exposure of the cells to deferoxamine and SnPP or deferoxamine and FeCl3 did not result in increased toxicity. These results implicate iron as the toxic element but indicate that the iron is only toxic when presented to the cell bound to protoporphyrin, such as found in hemin.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: NEW YORK MED COLL,DEPT MED,DIV NEOPLAST DIS,VALHALLA,NY 10595.

Publication date: January 1, 1993

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more